Back to home
EDSA logo

Is EDSA (Edesa Biotech, Inc.) Halal or Haram?

NASDAQ Capital MarketHealthcareBiotechnology$73.9M2026-04-27
EDSA is Halal4/4 screens passed

Edesa Biotech comfortably passes all AAOIFI financial screens, making it a fully shariah-compliant investment. The company operates entirely debt-free with a 0.0% debt-to-market cap ratio, and its cash reserves sit comfortably at 14.6% of market capitalization. Furthermore, it generates zero interest income, ensuring its revenues remain pure from an Islamic finance perspective.

Price Chart (5D)

$5.34-1.34 (-20.06%)
2026-06-082026-06-01

EDSA — Last 7 Days

DateOpenHighLowCloseVolumeChange
2026-06-085.745.844.945.37303K-6.45%
2026-06-057.617.615.015.46765K-28.25%
2026-06-046.807.456.697.09145K+4.26%
2026-06-036.787.096.516.86150K+1.18%
2026-06-026.757.786.736.83237K+1.19%
2026-06-017.057.056.496.69364K-5.11%
2026-05-297.757.797.197.22247K-6.84%

Discussion

Sign in to join the discussion

Loading comments...

Shariah Screening Details for EDSA

Business Activity

Permissible

Edesa Biotech passes the business activity screen as its core operations of developing clinical-stage treatments like EB05 for ARDS and EB01 for dermatitis are permissible healthcare activities.

Debt / Market Cap

0.00%

Debt: $0Threshold: ≤33%

Interest Income

0.00%

Interest: $2,558Threshold: ≤5%

Cash & Securities

14.60%

Cash: $10.8MThreshold: ≤33%

About Edesa Biotech, Inc. (EDSA)

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for inflammatory and immune-related diseases. Its lead product candidates include EB05, a monoclonal antibody in Phase 3 trials for acute respiratory distress syndrome, and EB01, a topical treatment for chronic allergic contact dermatitis.

For Muslim investors, EDSA represents a clear Halal investment opportunity within the biotechnology sector. The stock successfully passes all four AAOIFI shariah screens, meaning its core healthcare operations and financial structures align completely with Islamic principles.

From an Islamic finance perspective, Edesa Biotech's balance sheet is exceptionally clean. The company currently carries no interest-bearing debt (0.0% against market cap) and generates no impermissible interest income, providing peace of mind for halal portfolio builders. Its cash and securities ratio of 14.6% also remains safely below the 33% maximum limit.

Since biotechnology firms often rely on future licensing deals or capital raises to fund ongoing clinical trials, Muslim investors should periodically monitor EDSA's balance sheet. Any future conventional debt financing could alter its current zero-debt status and affect its shariah compliance.

CEO

Pardeep Nijhawan

Employees

16

IPO Date

2010-06-21

Headquarters

Markham, ON, CA

EDSA Key Financial Statistics

Revenue

$0

Net Income

$-7.2M

EPS (Diluted)

$-1.27

Stock Price

8.86

Beta

-0.68

52-Week Range

0.72-9.6341

Total Debt

$0

Total Equity

$12.5M

Current Ratio

10.67

EDSA Financial Health & Profitability

Profit Margins

Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%

Net Cash

$10.8M

Cash: $10.8M — Debt: $0

R&D Spending

$3.7M

% of Revenue

0%

Frequently Asked Questions About EDSA

Is EDSA (Edesa Biotech, Inc.) stock halal to invest in?
Based on our AAOIFI-standard shariah screening, EDSA is Halal and considered permissible for Muslim investors. It passed all 4 of 4 compliance screens including business activity review, debt-to-market-cap ratio (0.00% vs ≤33% threshold), interest income ratio (0.00% vs ≤5% threshold), and cash & securities ratio (14.60% vs ≤33% threshold).
What does Edesa Biotech, Inc. do?
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for inflammatory and immune-related diseases. Its lead product candidates include EB05, a monoclonal antibody in Phase 3 trials for acute respiratory distress syndrome, and EB01, a topical treatment for chronic allergic contact dermatitis. For Muslim investors, EDSA represents a clear Halal investment opportunity within the biotechnology sector. The stock successfully passes all four AAOIFI shariah screens, meaning its core healthcare operations and financial structures align completely with Islamic principles. From an Islamic finance perspective, Edesa Biotech's balance sheet is exceptionally clean. The company currently carries no interest-bearing debt (0.0% against market cap) and generates no impermissible interest income, providing peace of mind for halal portfolio builders. Its cash and securities ratio of 14.6% also remains safely below the 33% maximum limit. Since biotechnology firms often rely on future licensing deals or capital raises to fund ongoing clinical trials, Muslim investors should periodically monitor EDSA's balance sheet. Any future conventional debt financing could alter its current zero-debt status and affect its shariah compliance. Edesa Biotech, Inc. operates in the Healthcare sector under the Biotechnology industry and is headquartered in Markham, ON, CA. The company is led by CEO Pardeep Nijhawan and employs approximately 16 people.
What screening criteria were used for EDSA?
EDSA was screened using AAOIFI-based shariah compliance criteria. Four tests are applied: (1) Business Activity — the company's core business must not derive primary income from haram (prohibited) activities such as alcohol, gambling, tobacco, or interest-based finance. (2) Debt-to-Market-Cap — total debt must not exceed 33% of market capitalization. (3) Interest Income — interest income must not exceed 5% of total revenue. (4) Cash & Securities — cash and interest-bearing securities must not exceed 33% of market cap. EDSA passed 4 of these 4 screens.
Does EDSA require income purification?
Although EDSA passes all shariah screens, it does earn $2,558 in interest income (0.00% of revenue). Many scholars recommend purifying this portion by donating the equivalent percentage of any dividends received to charity. For example, if you receive $100 in dividends, you would donate approximately $0.00 to purify the income.
When was EDSA last screened?
EDSA was last screened on 2026-04-27. Shariah compliance status can change as companies report new financial data, acquire new businesses, or shift revenue streams. We recommend checking back periodically for the most up-to-date screening results.

Disclaimer

This shariah compliance assessment for EDSA (Edesa Biotech, Inc.) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-04-27.

Other Halal Stocks in Healthcare